ARVINAS INC. - COMMON STOCK

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

10 Dec 2024 09:05:00 By Nasdaq GlobeNewswire

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

27 Nov 2024 07:00:31 By Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

25 Nov 2024 17:35:18 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 Nov 2024 07:00:13 By Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

30 Oct 2024 07:00:45 By Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

22 Oct 2024 16:05:06 By Nasdaq GlobeNewswire

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

21 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

29 Aug 2024 07:00:48 By Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

24 Jun 2024 16:37:13 By Nasdaq GlobeNewswire

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21 Jun 2024 07:00:51 By Nasdaq GlobeNewswire

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

17 Jun 2024 07:00:03 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

03 Jun 2024 16:30:00 By Nasdaq GlobeNewswire

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

23 May 2024 17:00:15 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

16 May 2024 06:00:45 By Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

09 May 2024 16:42:04 By Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

07 May 2024 07:00:11 By Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24 Apr 2024 16:30:38 By Nasdaq GlobeNewswire

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

11 Apr 2024 07:00:49 By Nasdaq GlobeNewswire